Introducing New Blogger Bob Bohrer

bohrerBob Bohrer is a Professor of Law at California Western School of Law.  Having joined the faculty in 1982, Bob was one of the first full-time law teachers in the United States to concentrate on the emerging area of biotechnology law. His research is focused on the way in which drug development is influenced by a number of areas of law, including FDA approval, patent law, insurance and reimbursement, and the First Amendment commercial speech doctrine.

Bob is Chair Elect of the Biolaw Section of the Association of American Law Schools.  He received a B.A.from Haverford College, a J.D. from the University of Illinois College of Law, and an LL.M. from Harvard Law School.  A member of the Illinois Bar since 1974, he practiced with the Chicago firm of Bell, Boyd & Lloyd before entering law teaching.  While at California Western Bob developed an interdisciplinary program for lawyers, scientists, and business executives to explore issues of concern to the developing biotech industry, leading to his appointment as Director of Biotechnology Programs at the Center for Molecular Genetics of the University of California-San Diego from 1992-1999.  Bob has served on numerous boards, including those of Hygeia Pharmaceuticals (now Viventia Bio), Myelos Neurosciences (successfully acquired by a larger company), and the La Jolla Institute for Experimental Medicine.  Bob was also a member of the Institutional Biosafety Committee at UCSD and the Internal Review of Conflicts Committee of the UCSD-VA.

Bob edited the book From Research to Revolution: Scientific, Business, and Legal Perspectives on the New Biotechnology (1987) and authored A Guide to Biotechnology Law and Business which was published by Carolina Academic Press in 2007.  He served as Executive Editor of Biotechnology Law Report from 1999-2011 and now blogs on pharmaceutical policy at  He is currently writing a book with the working title “An Information Prescription for Pharmaceutical Policy.”

Selected Publications:

Reach-Through Claims For Drug Target Patents: Rx For Pharmaceutical Policy, 26 Nature Biotechnology 55 (January 2008).

Between a Rock and a Hard Place: University Research After Merck and Madey and the University of Rochester, 24 Biotechnology L. Rep. 713 (2005).

Longevity Research and Bioethics, 23 Biotechnology L. Rep. 542 (2004).

It’s the Antigen Stupid: A Risk/Reward Approach to the Problem of Orphan Drug Act Exclusivity for Monoclonal Antibody Therapeutics, 5 Columbia Sci. and Tech. L.Rev.1 (2003).

The Petrie-Flom Center Staff

The Petrie-Flom Center staff often posts updates, announcements, and guests posts on behalf of others.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.